Bioness has announced the first successful implants of its StimRouter Neuromodulation System for the treatment of chronic pain at Women's College Hospital in Toronto, Canada. Following approval by Health Canada in January, the peripheral nerve stimulation device is now available in Canada, the United States and Europe, giving patients a non-opioid, permanent solution for the treatment of chronic pain of a peripheral nerve origin, excluding pain in the craniofacial region.
"Significant advances in the miniaturisation and durability of neuromodulation devices have provided interventional pain physicians with the right tools, like the StimRouter PNS System, to treat chronic pain related to nerve injuries, trauma, stroke and other irreversible damages with a simple, minimally invasive procedure. Effective PNS may help reduce or even discontinue opioids that are commonly prescribed for these patients," said Dr. Michael Gofeld, pain physician at Women's College Hospital and first to implant the StimRouter in Canada.
"The approval of StimRouter in Canada is a tremendous step forward as we expand our non-drug solution to chronic pain of a peripheral nerve origin with a robust, validated, treatment for people seeking pain relief," said Todd Cushman, President and CEO of Bioness.
"It is our hope that the StimRouter will offer reduced pain and increased activity for patients and an answer for doctors facing the serious realities of the opioid epidemic. We believe this step forward in Canada indicates the conversation on pain is shifting in the right direction toward simple, reversible, permanent solutions."
StimRouter is the first minimally-invasive, long-term neuromodulation medical device cleared and available in the United States, Europe, and Canada. The patient controlled medical device is an adjunct to other modes of therapy and is being well received by patients and clinicians alike.
To date, more than 20 nerve locations have been targeted on many hundreds of patients worldwide, signaling the broad utility and effectiveness of this technology.